Cancer claims and specialty drugs lead to rise in stop-loss costs: QBE & more related News Here
The annual report, which is based on QBE’s proprietary claims data, found that neoplasms accounted for 36% of all stop-loss claim reimbursements, maintaining its position as the leading diagnosis at all deductible levels. At the $200,000 deductible level, severity of neoplasm claims increased 12% from the average in previous years, while frequency increased nearly 30%….
